NO873492D0 - Fremgangsmaate for fremstilling av antifungale preparater. - Google Patents

Fremgangsmaate for fremstilling av antifungale preparater.

Info

Publication number: NO873492D0
Authority: NO; Norway
Prior art keywords: vesicles; fungal infections; procedure; preparation; systemic fungal
Prior art date: 1986-08-21

Application number

NO873492A

Other languages

English (en)

Other versions

NO873492L (no

NO174833C (no

NO174833B (no

Inventor

Jill Adler-Moore

Ronald Carl Gamble

Richard Thomas Proffitt

Original Assignee

Vestar Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-08-21

Filing date

1987-08-19

Publication date

1987-08-19

1987-08-19 Application filed by Vestar Inc filed Critical Vestar Inc

1987-08-19 Publication of NO873492D0 publication Critical patent/NO873492D0/no

1988-02-22 Publication of NO873492L publication Critical patent/NO873492L/no

1994-04-11 Publication of NO174833B publication Critical patent/NO174833B/no

1994-07-20 Publication of NO174833C publication Critical patent/NO174833C/no

Links

230000000843 anti-fungal effect Effects 0.000 title abstract 4
229940121375 antifungal agent Drugs 0.000 title abstract 4
238000000034 method Methods 0.000 title abstract 2
238000002360 preparation method Methods 0.000 title 2
206010017533 Fungal infection Diseases 0.000 abstract 2
208000031888 Mycoses Diseases 0.000 abstract 2
230000003115 biocidal effect Effects 0.000 abstract 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
239000002245 particle Substances 0.000 abstract 2
150000004291 polyenes Chemical class 0.000 abstract 2
230000009885 systemic effect Effects 0.000 abstract 2
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 abstract 1
239000007983 Tris buffer Substances 0.000 abstract 1
150000001412 amines Chemical class 0.000 abstract 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 abstract 1
229960003942 amphotericin b Drugs 0.000 abstract 1
239000003242 anti bacterial agent Substances 0.000 abstract 1
229940088710 antibiotic agent Drugs 0.000 abstract 1
150000001720 carbohydrates Chemical class 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
229960000988 nystatin Drugs 0.000 abstract 1
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 abstract 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
150000003904 phospholipids Chemical class 0.000 abstract 1
239000000243 solution Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Nanotechnology (AREA)
Dispersion Chemistry (AREA)
Crystallography & Structural Chemistry (AREA)
Medical Informatics (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO873492A 1986-08-21 1987-08-19 Fremgangsmåte for fremstilling av et injiserbart preparat NO174833C (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US89906486A	1986-08-21	1986-08-21

Publications (4)

Publication Number	Publication Date
NO873492D0 true NO873492D0 (no)	1987-08-19
NO873492L NO873492L (no)	1988-02-22
NO174833B NO174833B (no)	1994-04-11
NO174833C NO174833C (no)	1994-07-20

Family

ID=25410437

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO873492A NO174833C (no)	1986-08-21	1987-08-19	Fremgangsmåte for fremstilling av et injiserbart preparat

Country Status (14)

Country	Link
US (1)	US5874104A (no)
EP (1)	EP0260811B1 (no)
JP (1)	JPH0615475B2 (no)
KR (1)	KR950013747B1 (no)
AT (1)	ATE66597T1 (no)
AU (1)	AU606880B2 (no)
CA (1)	CA1292184C (no)
DE (1)	DE3772498D1 (no)
DK (1)	DK168982B1 (no)
ES (1)	ES2051740T3 (no)
GR (1)	GR3002852T3 (no)
HK (1)	HK115393A (no)
IE (1)	IE60901B1 (no)
NO (1)	NO174833C (no)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1338736C (fr) *	1986-12-05	1996-11-26	Roger Baurain	Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
FR2620028B2 (fr) *	1986-12-05	1994-02-25	Ire Celltarg Sa	Procede de preparation de microcristaux comportant a titre de substance active, notamment de l'amphotericine b, microcristaux obtenus et composition pharmaceutique en comprenant
US4812312A (en) *	1987-03-03	1989-03-14	Board Of Regents Of The University Of Texas System	Liposome-incorporated nystatin
US5616334A (en) *	1987-03-05	1997-04-01	The Liposome Company, Inc.	Low toxicity drug-lipid systems
US6406713B1 (en)	1987-03-05	2002-06-18	The Liposome Company, Inc.	Methods of preparing low-toxicity drug-lipid complexes
CA1338702C (en) *	1987-03-05	1996-11-12	Lawrence D. Mayer	High drug:lipid formulations of liposomal- antineoplastic agents
US4999199A (en) *	1988-11-10	1991-03-12	Board Of Regents, The University Of Texas System	Pharmaceutical formulations: liposomes incorporating aromatic polyene antibiotics
KR0151704B1 (ko) *	1989-11-27	1998-10-15	아만 히데아키	지방 유제
WO1992011841A1 (en) *	1991-01-14	1992-07-23	Board Of Regents, The University Of Texas	Anti-hiv activity of liposomal nystatin and amphotericin b
EP0664130A1 (en) *	1991-10-25	1995-07-26	Senju Pharmaceutical Co., Ltd.	External preparation for treating hemorrhoidal diseases
JP2915296B2 (ja) *	1993-08-30	1999-07-05	宇野潤	抗真菌製剤
GB9519654D0 (en) *	1995-09-27	1995-11-29	Nycomed Imaging As	Stabilised phospholipid compositions
EP0876140B1 (de)	1996-01-25	2003-10-15	Schering Aktiengesellschaft	Verbesserte kontrastmittenlösungen für die intravasale anwendung
GB9721901D0 (en) *	1997-10-16	1997-12-17	Univ Manchester	Particles
IL136342A0 (en) *	1997-12-01	2001-05-20	Yissum Res Dev Co	Formulation for topical treatment of skin infections
IT1301807B1 (it) *	1998-06-25	2000-07-07	Tiberio Bruzzese	Formulazioni farmaceutiche iniettabili di derivati della partricina.
US6613352B2 (en)	1999-04-13	2003-09-02	Universite De Montreal	Low-rigidity liposomal formulation
US6413537B1 (en)	2000-03-10	2002-07-02	Wisconsin Alumni Research Foundation	Nystatin formulation having reduced toxicity
JP4786041B2 (ja) *	2001-03-02	2011-10-05	丸善製薬株式会社	渋味、収斂味を低減する方法および渋味、収斂味低減ハス胚芽抽出物製剤
US7651689B2 (en) *	2002-11-15	2010-01-26	Albert Einstein College Of Medicine Of Yeshiva University	Methods of applying ionization radiation for therapy of infections
US20090099031A1 (en) *	2005-09-27	2009-04-16	Stemmer Willem P	Genetic package and uses thereof
US20070191272A1 (en) *	2005-09-27	2007-08-16	Stemmer Willem P	Proteinaceous pharmaceuticals and uses thereof
US7855279B2 (en)	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
US7846445B2 (en) *	2005-09-27	2010-12-07	Amunix Operating, Inc.	Methods for production of unstructured recombinant polymers and uses thereof
US8067433B2 (en)	2005-11-09	2011-11-29	Zalicus Inc.	Methods, compositions, and kits for the treatment of ophthalmic disorders
US20070190127A1 (en)	2005-12-30	2007-08-16	Mingdong Zhou	Extended release of neuregulin for improved cardiac function
WO2009023270A2 (en) *	2007-08-15	2009-02-19	Amunix, Inc.	Compositions and methods for modifying properties of biologically active polypeptides
EP2564857B1 (en)	2008-03-06	2017-05-03	Anacor Pharmaceuticals, Inc.	Boron-containing small molecules as anti-inflammatory agents
US8716448B2 (en)	2009-02-03	2014-05-06	Amunix Operating Inc.	Coagulation factor VII compositions and methods of making and using same
EP3178835B1 (en)	2009-02-03	2019-04-10	Amunix Pharmaceuticals, Inc.	Extended recombinant polypeptides and compositions comprising same
CN102481331B (zh)	2009-06-08	2017-09-22	阿穆尼克斯运营公司	葡萄糖调节多肽及其制备和使用方法
CA2764105A1 (en)	2009-06-08	2010-12-16	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
CA2767646C (en)	2009-07-10	2019-01-29	President And Fellows Of Harvard College	Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
RU2481100C2 (ru) *	2009-10-16	2013-05-10	Лайфкеа Инновейшнз Пвт. Лтд.	Новая лекарственная форма для лечения грибковой инфекции
WO2011053675A2 (en)	2009-10-30	2011-05-05	Cns Therapeutics, Inc.	Improved neurturin molecules
WO2011075688A1 (en)	2009-12-18	2011-06-23	Exodos Life Sciences Limited Partnership	Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
US8716478B2 (en)	2010-01-27	2014-05-06	Anacor Pharmaceuticals, Inc.	Boron-containing small molecules
JP5936002B2 (ja) *	2010-11-19	2016-06-15	北海道公立大学法人札幌医科大学	組合わせ医薬製剤
DK3564260T5 (da)	2012-02-15	2024-09-02	Bioverativ Therapeutics Inc	Faktor viii-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
EA201491388A1 (ru)	2012-02-15	2015-01-30	Байоджен Айдек Ма Инк.	Рекомбинантные белки фактора viii
EP2858672B1 (en)	2012-06-08	2018-04-04	Alkermes, Inc.	Fusion polypeptides comprising mucin-domain polypeptide linkers
WO2015023891A2 (en)	2013-08-14	2015-02-19	Biogen Idec Ma Inc.	Factor viii-xten fusions and uses thereof
CA2943190A1 (en)	2014-03-25	2015-10-01	The Government Of The United States Of America As Represented By The Secretary Of The Army	Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin
JP2017536421A (ja)	2014-12-01	2017-12-07	アケリオスセラピューティクス，インコーポレーテッド	片頭痛及び疼痛に関連する状態を処置するための方法及び組成物
CN108348774A (zh)	2015-08-03	2018-07-31	哈佛大学校长及研究员协会	带电离子通道阻断剂及其应用
MX2018001497A (es)	2015-08-03	2018-05-15	Bioverativ Therapeutics Inc	Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
US20180327436A1 (en)	2015-11-06	2018-11-15	Adjuvance Technologies, Inc.	Triterpene saponin analogues
WO2018035380A1 (en)	2016-08-17	2018-02-22	Solstice Biologics, Ltd.	Polynucleotide constructs
IL308416B2 (en)	2016-12-02	2025-08-01	Bioverativ Therapeutics Inc	Methods of treating hemophilic arthropathy using chimeric clotting factors
US11597744B2 (en)	2017-06-30	2023-03-07	Sirius Therapeutics, Inc.	Chiral phosphoramidite auxiliaries and methods of their use
CA3075822A1 (en)	2017-10-16	2019-04-25	Adjuvance Technologies, Inc.	Triterpene saponin analogues
MA52630B1 (fr)	2018-05-18	2025-07-31	Bioverativ Therapeutics Inc.	Procédés de traitement de l'hémophilie a
JP7678757B2 (ja)	2019-03-11	2025-05-16	ノシオンセラピューティクス，インコーポレイテッド	荷電したイオンチャンネル遮断薬および使用方法
US10786485B1 (en)	2019-03-11	2020-09-29	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
US10780083B1 (en)	2019-03-11	2020-09-22	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
CN113924094A (zh)	2019-03-11	2022-01-11	诺西恩医疗公司	酯取代的离子通道阻滞剂及其使用方法
CA3129131A1 (en)	2019-03-11	2020-09-17	Bridget Mccarthy Cole	Charged ion channel blockers and methods for use
US20220307013A1 (en)	2019-08-30	2022-09-29	The Regents Of The University Of California	Gene fragment overexpression screening methodologies, and uses thereof
US10842798B1 (en)	2019-11-06	2020-11-24	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
EP4054586A4 (en)	2019-11-06	2023-11-22	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
JP7708777B2 (ja)	2020-03-11	2025-07-15	ノシオンセラピューティクス，インコーポレイテッド	荷電したイオンチャンネル遮断薬および使用方法
US12162851B2 (en)	2020-03-11	2024-12-10	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
EP4172179A4 (en)	2020-06-25	2024-11-20	Amunix Pharmaceuticals, Inc.	HER-2 TARGETED BISPECIFIC COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
IL306074A (en)	2021-03-24	2023-11-01	Alkermes Inc	UPAR antibodies and fusion proteins with them
EP4493153A1 (en)	2022-03-14	2025-01-22	Pfizer Inc.	Methods for producing an adjuvant
KR20240164801A (ko)	2022-03-21	2024-11-20	더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈	암포테리신 b의 지질-코팅된 결정을 포함하는 이온 채널 보형 조성물
KR20250113501A (ko)	2022-12-01	2025-07-25	화이자 인코포레이티드	폐렴구균 접합체 백신 제형
WO2025057058A1 (en)	2023-09-13	2025-03-20	Pfizer Inc.	Methods for producing an adjuvant
WO2025191415A1 (en)	2024-03-11	2025-09-18	Pfizer Inc.	Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4310505A (en) *	1979-11-08	1982-01-12	California Institute Of Technology	Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances
US4497791A (en) *	1983-02-10	1985-02-05	Vestar Research Incorporated	Method for labeling phagocytic cells
GB2135647A (en) *	1983-02-15	1984-09-05	Squibb & Sons Inc	Method of preparing liposomes and products produced thereby
PT78628B (en) *	1984-05-02	1986-06-18	Liposome Co Inc	Pharmaceutical composition with reduced toxicity
US4880635B1 (en) *	1984-08-08	1996-07-02	Liposome Company	Dehydrated liposomes
IE58659B1 (en) *	1984-10-22	1993-11-03	Vestar Inc	Use of a micellular particle composition encapsulating a chemotherapeutic agent for intravenous targeting to tumors
US4753788A (en) *	1985-01-31	1988-06-28	Vestar Research Inc.	Method for preparing small vesicles using microemulsification
US4766046A (en) *	1985-09-27	1988-08-23	Liposome Technology, Inc.	Stabilized liposome/amphotericin composition and method
US4812312A (en) *	1987-03-03	1989-03-14	Board Of Regents Of The University Of Texas System	Liposome-incorporated nystatin

1987
- 1987-08-11 IE IE214887A patent/IE60901B1/en not_active IP Right Cessation
- 1987-08-14 EP EP87307221A patent/EP0260811B1/en not_active Expired - Lifetime
- 1987-08-14 ES ES87307221T patent/ES2051740T3/es not_active Expired - Lifetime
- 1987-08-14 DE DE8787307221T patent/DE3772498D1/de not_active Expired - Lifetime
- 1987-08-14 AT AT87307221T patent/ATE66597T1/de not_active IP Right Cessation
- 1987-08-18 AU AU77160/87A patent/AU606880B2/en not_active Expired
- 1987-08-19 NO NO873492A patent/NO174833C/no not_active IP Right Cessation
- 1987-08-19 CA CA000544830A patent/CA1292184C/en not_active Expired - Lifetime
- 1987-08-20 DK DK434187A patent/DK168982B1/da not_active IP Right Cessation
- 1987-08-20 KR KR1019870009101A patent/KR950013747B1/ko not_active Expired - Lifetime
- 1987-08-21 JP JP62208049A patent/JPH0615475B2/ja not_active Expired - Fee Related
1991
- 1991-10-08 GR GR91401494T patent/GR3002852T3/el unknown
1993
- 1993-10-28 HK HK1153/93A patent/HK115393A/en not_active IP Right Cessation
1995
- 1995-06-06 US US08/467,864 patent/US5874104A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
ES2051740T3 (es)	1994-07-01
AU7716087A (en)	1988-02-25
ATE66597T1 (de)	1991-09-15
EP0260811B1 (en)	1991-08-28
DE3772498D1 (de)	1991-10-02
JPH0615475B2 (ja)	1994-03-02
GR3002852T3 (en)	1993-01-25
DK434187D0 (da)	1987-08-20
AU606880B2 (en)	1991-02-21
EP0260811A3 (en)	1988-07-20
NO873492L (no)	1988-02-22
DK168982B1 (da)	1994-07-25
IE60901B1 (en)	1994-08-24
KR880002531A (ko)	1988-05-09
CA1292184C (en)	1991-11-19
HK115393A (en)	1993-11-05
KR950013747B1 (ko)	1995-11-15
NO174833C (no)	1994-07-20
JPS6366123A (ja)	1988-03-24
IE872148L (en)	1988-02-21
NO174833B (no)	1994-04-11
US5874104A (en)	1999-02-23
EP0260811A2 (en)	1988-03-23
DK434187A (da)	1988-02-22

Publication	Publication Date	Title
NO873492L (no)	1988-02-22	Fremgangsmaate for fremstilling av antifungale preparater.
AU5418486A (en)	1987-04-16	Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles and methods for using same for tumor therapy
BR1100687A (pt)	2000-02-08	Formulações de agentes antineoplásticos lipossÈmicos com proporção elevada de droga com lipìdio
GR1000074B (el)	1990-10-31	Λιποειδη σφαιριδια (κυστιδια) για ενδοπεριτονειακη χορηγηση θεραπευτικων παραγοντων.
CA2233961A1 (en)	1997-04-10	Stimulation of hair follicles
NO901852L (no)	1990-08-01	Fremgangsmaate for fremstilling av liposomer.
EP0335133A3 (en)	1990-05-16	Drug delivery using pulmonary surfactant fo facilitate absorption
NO180147C (no)	1997-02-26	Fremgangsmåte for fremstilling av HDLC eller et liposom innbefattende et polyen-antisopp-antibiotikum og et lipid
KR950700725A (ko)	1995-02-20	리포솜 조성물(liposome composition)
EP0393145A4 (en)	1991-09-11	Spontaneous vesiculation of multilamellar liposomes
RU94027343A (ru)	1996-09-27	Липосомальная везикула с цитохромом с

Legal Events

Date	Code	Title	Description
2007-08-27	MK1K	Patent expired